Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line

Posted on | Posted on John Murphy | Leave a Comment on Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line

Authors:  Markus Aldén 1,Francisko Olofsson Falla 1,Daowei Yang 1,Mohammad Barghouth 1,Cheng Luan 1,Magnus Rasmussen 2 andYang De Marinis 1,*1Department of Clinical Sciences, Lund University, 20502 Malmö, Sweden2Infection Medicine, Department of Clinical Sciences, Lund University, 22362 Lund, Sweden Abstract Preclinical studies of COVID-19 mRNA vaccine BNT162b2, developed by Pfizer and BioNTech, showed reversible hepatic effects in animals that received the BNT162b2 injection. Furthermore, a […]

Long-term cardiovascular outcomes of COVID-19

Posted on | Posted on John Murphy | Leave a Comment on Long-term cardiovascular outcomes of COVID-19

Authors: Yan Xie, Evan Xu, Benjamin Bowe & Ziyad Al-Aly Nature Medicine (2022)Cite this article368k Accesses Citations14239 AltmetricMetrics Abstract The cardiovascular complications of acute coronavirus disease 2019 (COVID-19) are well described, but the post-acute cardiovascular manifestations of COVID-19 have not yet been comprehensively characterized. Here we used national healthcare databases from the US Department of Veterans Affairs to build a cohort of […]

Fighting COVID-19 with milk?

Posted on | Posted on John Murphy | Leave a Comment on Fighting COVID-19 with milk?

Authors: Elsevier As the COVID-19 pandemic continues to claim lives around the world, dairy scientists may have a surprising role to play. In a new report published in the Journal of Dairy Science, scientists from the University of Michigan (Ann Arbor, MI, USA) and Glanbia PLC Research and Development (Twin Falls, ID, USA) have collaborated to […]

COVID-19 and cerebrovascular diseases: a comprehensive overview

Posted on | Posted on John Murphy | Leave a Comment on COVID-19 and cerebrovascular diseases: a comprehensive overview

Authors: Georgios Tsivgoulis, Lina Palaiodimou, Ramin Zand First Published December 8, 2020 Review Article Find in PubMed https://doi.org /10.1177/1756286420978004 Abstract Neurological manifestations are not uncommon during infection with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A clear association has been reported between cerebrovascular disease and coronavirus disease 2019 (COVID-19). However, whether this association is causal or incidental is […]

Potential pharmacologic treatments for COVID-19 smell and taste loss: A comprehensive review

Posted on | Posted on John Murphy | Leave a Comment on Potential pharmacologic treatments for COVID-19 smell and taste loss: A comprehensive review

Authors: Elnaz Khani,aSajad Khiali,aSamineh Beheshtirouy,a and Taher Entezari-Malekia,b,∗ Eur J Pharmacol. 2021 Dec 5; 912: 174582.Published online 2021 Oct 19. doi:  10.1016/ j.ejphar.2021.174582 PMCID: PMC8524700PMID: 34678243 Abstract The acute loss of taste and smell following COVID-19 are hallmark symptoms that affect 20–85% of patients. However, the pathophysiology and potential treatments of COVID-19 smell and taste loss are not fully understood. We […]

Smell and Taste Loss Recovery Time in COVID-19 Patients and Disease Severity

Posted on | Posted on John Murphy | Leave a Comment on Smell and Taste Loss Recovery Time in COVID-19 Patients and Disease Severity

Authors: Athanasia Printza,1,*Mihalis Katotomichelakis,2Konstantinos Valsamidis,1Symeon Metallidis,3Periklis Panagopoulos,4Maria Panopoulou,5Vasilis Petrakis,4 and Jannis Constantinidis1 J Clin Med. 2021 Mar; 10(5): 966.Published online 2021 Mar 2. doi: 10.3390/jcm10050966 PMCID: PMC7957474PMID: 33801170 Abstract A significant proportion of people infected with SARS-CoV-2 report a new onset of smell or taste loss. The duration of the chemosensory impairment and predictive factors of recovery are still unclear. We aimed […]

Protection against Covid-19 by BNT162b2 Booster across Age Groups

Posted on | Posted on John Murphy | Leave a Comment on Protection against Covid-19 by BNT162b2 Booster across Age Groups

Authors. Yinon M. Bar-On, M.Sc., Yair Goldberg, Ph.D., Micha Mandel, Ph.D., Omri Bodenheimer, M.Sc., Laurence Freedman, Ph.D., Sharon Alroy-Preis, M.D., Nachman Ash, M.D., Amit Huppert, Ph.D., and Ron Milo, Ph.D. Abstract BACKGROUND After promising initial results from the administration of a third (booster) dose of the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) to persons 60 years of age or older, the booster campaign in […]

Long COVID in Children

Posted on | Posted on John Murphy | Leave a Comment on Long COVID in Children

Observations From a Designated Pediatric Clinic Authors: Ashkenazi-Hoffnung, Liat MD*,†; Shmueli, Einat MD*,†; Ehrlich, Shay MD*,†; Ziv, Adi MD*,†; Bar-On, Ophir MD*,†; Birk, Einat MD*,†; Lowenthal, Alexander MD*,†; Prais, Dario MD*,† Abstract Systematic data are lacking on pediatric long COVID. This study prospectively assessed 90 children with persistent symptoms who presented to a designated multidisciplinary […]

Spotting Long COVID Symptoms in Children

Posted on | Posted on John Murphy | Leave a Comment on Spotting Long COVID Symptoms in Children

Authors: Katie Sweeney Published on November 17, 2021 Categories: COVID-19, Hospital Programs It’s one of the more mysterious aspects of COVID-19—a condition called long COVID. While most people recover from the virus within two to four weeks, others can struggle for months afterward with lingering, often debilitating symptoms. Long COVID has been most commonly talked about in adults, but children […]